Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer-Reference-Cited by-同舟云学术

Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer

Published:2019 Issue:4 Volume:4 Page:e000519
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Cardone Claudia^ORCID,Martinelli Erika,Troiani Teresa,Sforza Vincenzo,Avallone Antonio,Nappi Anna,Montesarchio Vincenzo,Andreozzi Francesca,Biglietto Maria,Calabrese Filomena,Bordonaro Roberto,Cordio Stefano,Bregni Giacomo,Febbraro Antonio,Garcia-Carbonero Rocio,Feliu Jaime,Cervantes Andrés^ORCID,Ciardiello Fortunato

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference23 articles.

1. Effect of application and intensity of bevacizumab-based maintenance after induction chemotherapy with bevacizumab for metastatic colorectal cancer: a meta-analysis;Stein;Clin Colorectal Cancer,2016

2. Maintenance therapy in colorectal cancer: moving the Artillery down while keeping an eye on the enemy;Aprile;Clin Colorectal Cancer,2016

3. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial;Wasan;Lancet Oncol,2014

4. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study;Aranda;Eur J Cancer,2018

5. First-Line FOLFOX plus panitumumab (Pan) followed by 5FU/LV plus pan or single-agent pan as maintenance therapy in patients with Ras wild-type metastatic colorectal cancer (mCRC): the Valentino study;Pietrantonio;JCO,2018

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study;ESMO Open;2023-02

2. Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials;Annals of Oncology;2023-01

3. Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review;Translational Cancer Research;2022-01

4. The JPJDF has Synergistic Effect with Fluoropyrimidine in the Maintenance Therapy for Metastatic Colorectal Cancer;Recent Patents on Anti-Cancer Drug Discovery;2020-12-07

5. ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy;ESMO Open;2020